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ABSTRACT
Inhibition of Escherichia coli ATP Synthase by Polyphenols and Their Derivatives
by
Prasanna Keerthi Dadi

We have studied the inhibitory effect of natural and structurally modified polyphenols on Escherichia

coli ATP synthase to test (I) if the beneficial dietary effects of polyphenols are related to their inhibitory
actions on ATP synthase, (II) if inhibitory effects of polyphenolic compound could be augmented through
structural modifications, and (III) if they can act as antimicrobial agent through their actions on ATP
synthesis. X-ray crystal structures of polyphenol binding sites suggested that polyphenols bind at a
distinct polyphenol binding pocket, at the interface of α,β,γ-subunits. We found that both natural and
modified polyphenols inhibit E. coli ATP synthase to varying degrees and structural modifications
resulted in augmented inhibition. Inhibition was reversible in all cases. Both natural and modulated
compounds inhibited E. coli cell growth to varying degrees. We conclude that dietary benefits of
polyphenols may be in part due to the inhibition of ATP synthase.
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CHAPTER 1
INTRODUCTION

ATP synthase is the fundamental means of cellular energy production in animals, plants,
and almost all microorganisms by oxidative or photo phosphorylation. The energy from ATP is
used for various biochemical reactions like transport of nutrients, muscle contraction, nucleic
acid synthesis, protein synthesis, active transport, etc. ATP synthase is a membrane bound
enzyme that is found in the inner mitochondrial membrane and in the thylakoid membrane of
chloroplasts of eukaryotic cells. In bacteria it is found embedded in the plasma membrane. ATP
synthase has homology in amino acid sequence and is exceptionally conserved throughout
evolution resulting in similar mechanism in ATP synthesis and hydrolysis in most of the
organisms. The simplest of all is that of E. coli with 8 subunits in 2 main portions. A membrane
embedded Fo and a catalytic F1. F1 consists of α3ß3γδε subunits and Fo has ab2c10 as shown in Fig.
1. ATP hydrolysis and synthesis occur on three catalytic sites in the F1 sector, while proton
transport occurs through the membrane embedded Fo (1,2).
The γ subunit is part of the “rotor” which is composed of γ, ε, and a ring of c subunits.
The “stator” composed of b2δ, prevents co-rotation of catalytic sites and the a subunit with the
rotor (3,4). Proton gradient-driven clockwise rotation of γ (as viewed from the membrane) leads
to ATP synthesis while anticlockwise rotation of γ results from ATP hydrolysis. The mechanism
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is essentially a rotary motor that is in fact the smallest known biological nanomotor. Detailed
review of ATP synthase structure and function has been reviewed (5-11).

Figure 1. The ATP Synthase of E. coli (Reproduced from (9) with permission; copyright
Elsevier). The enzyme consists of two sectors catalytic F 1 and membrane bound F o. F1 consists
of α3 β3 γ δ ε and F0 consists of ab2c10. In mitochondria and chloroplasts additional subunits are
present. The rotor stalk indicates the helical coiled-coil extension of the γ subunit into the
central cavity of the α3β3 hexagon. The rotor is composed of γ,ε , and a ring of c subunits. The
“stator” is composed of b2δ. The proton pathway lies between a and c subunits.
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ATP Synthase and its Role in Disease Conditions

ATP synthase malfunctioning has been documented as a basis for many human diseases
such as, cancer, heart disease, mitochondrial diseases, immune deficiency, cystic fibrosis,
diabetes, ulcers, and tuberculosis (5,12). Alteration of ATP synthase biogenesis may cause 2
types of defects: qualitative, when the enzyme is structurally altered and does not function
properly, and quantitative, when it is present in insufficient or adequate amounts (13). Most of
these alterations are due to variation in the biosynthesis of the enzyme that can be due to
mutations in subunit genes or in ancillary proteins essential for the enzyme assembly or in the
areas responsible for gene regulation.

Mutation in subunit a of ATP synthase causes severe impairment of ATP synthesis
resulting in a neurodegenerative disease known as Leigh syndrome (14). A mutation in the same
subunit causes a dysfunction of ATP synthase causing the neuropathy, ataxia, retinitis
pigmentosa syndrome, and the familial bilateral striatal necrosis (15,16). In Alzheimer’s disease
a deficiency of ATP synthase β subunit and the cytosolic accumulation of the α subunit has been
observed (17,18). The intraneuronal cytosolic build up of the α subunit is suspected to be
involved in the neurodegenerative process (16,18). Batten’s disease belonging to a group of
disorders called neuronal ceroid lipofuscinosis is caused by buildup of lipofuscins in the body's
tissues and subunit c of ATP synthase has been found as a predominant storage protein (15,16).
Circulation of the ATP synthase F6 subunit in the blood has been identified to be involved in the
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increase of blood pressure (19,20). It is also reported that the ATP synthase on the cell surface of
endothelial cells are associated with the angiogenesis process required for tumor growth (21-23).
As ATP synthase is implicated in many diseases it has been suggested and demonstrated
as a good molecular target for drugs in the treatment of various diseases and the regulation of
energy metabolism (24-28). One of the drugs developed for the treatment of tuberculosis, was
shown to be active against a number of drug-resistant strains of Mycobacterium tuberculosis.
Interestingly, it was found that 2 mutations in the mycobacterium ATP synthase Fo sector Csubunit, namely D32A and A63P, are responsible for the bacterial resistance to diarylquinoline
drugs and the new drug R207910, has been reported to block the synthesis of ATP by targeting
subunit c of ATP synthase and thus treating the disease (24,29,30). Another drug, Bz-423, which
was developed to treat the autoimmune disorder systemic lupus erythematosus, kills pathogenic
lymphocytes selectively by inducing apoptosis in lymphoid cells (31). It was found that the
apoptosis of lymphoid cells is due to the inhibition of the mitochondrial ATP synthase by Bz-423
through binding to the subunit known as oligomycin sensitivity-conferring protein (OSCP) (26).

For a long time, it was believed that ATP synthase was found only in mitochondria and
chloroplasts of eukaryotes where most cellular ATP synthesis takes place. However, recent
studies indicate that ATP synthase is even expressed on the extracellular surface of several
animal cell types such as endothelial cells of cancer tissues, making it an ideal recognition
molecule on cancer cells and could possibly be targeted therapeutically in the treatment of such
diseases by inhibiting the enzyme. Thus, identification of potent ATP synthase inhibitors may
allow the development of lead drugs for therapeutic treatments.
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Inhibition of ATP Synthase
Wide ranges of natural and synthetic compounds and molecules are known to bind and
inhibit ATP synthase. The inhibitors can be characterized into different groups based on the type
of bond formed with the enzyme, inhibitors can be grouped into either covalent or noncovalent
inhibitors (32). Covalent inhibitors include NBD-Cl (4-chloro-7-nitrobenzofurazan), DCCD
(dicyclohexylcarbodi-imide), and several reactive derivatives of ATP and ADP (33). The
noncovalent inhibitors include non-hydrolysable substrate analogues, azide, the natural inhibitor
protein IF1, the efrapeptins, the aurovertins, dietary phyto-polyphenols, nonpeptidyl lipophilic
cations, and amphiphilic peptides (34).

Another classification is based on the physical and chemical characteristics of the inhibitors
(2,35-40).
1) Peptide inhibitors: several types of peptide inhibitors have be identified and can be subdivided
into Helical Basic Peptide Inhibitors, Angiostatin, Enterostatin, Leucinostatins, Efrapeptins,
Tentoxin and its Derivatives.
2) Phytochemicals: are naturally occurring plant derivatives. They are known to posses
chemotherapeutic properties and are known to bind to multiple molecular targets in the body.
Phytochemicals are categorized into various groups, and among these are the polyphenols,
steroids such as estradiols, estrogen and its metabolites.
3) Polyketide inhibitors: are the polymers of 2-carbon ketide units synthesized
by the enzyme polyketide synthases. eg. Macrolides: apoptolidin, cytovaricin, oligomycin,
13

ossamycin, and venturicidin.
4) Organotin compounds and structural relatives: are Tin containing organic compounds. They
are classified into R4Sn, R3SnX, R2SnX2, and RSnX3.
5) Polyenic α-pyrone derivatives: α-Pyrone (or 2-pyrone) is a 6 membered cyclic unsaturated
Ester and its derivatives are known to inhibit ATP synthase. Eg. aurovertin, citreoviridin,
asteltoxin.
Other inhibitors can be grouped into cationic inhibitors, substrates and substrate analogs, amino
acid modifiers, and miscellaneous inhibitors (36).

Polyphenols

Polyphenolic compounds are a distant group of naturally occurring compounds
containing multiple phenolic functionalities. These compounds are primarily synthesized by
plants as secondary metabolites and are found in abundance in fruits and vegetables. Notable
sources of polyphenols can be found in berries, grapes, tea, citrus fruits, cocoa, nuts, and fresh
vegetables. Their dietary importance has been linked to their role as anti oxidants. They interact
with metal ions such as Fe2+ and prevent free radical formation in biological systems that are
responsible for the DNA damage (41).

Polyphenols are the subject of interest to many scientists for their medicinal, synthetic,
and industrial value. Plant derived polyphenols are known to have numerous biological activities.
They are found to be potential candidates for use as drugs and for the treatment of many diseases
like cancer, heart ailments, ulcer formation, bacterial infections, mutagenesis, neural disorders,
etc. They also block the action of enzymes and other substances that promote the growth of
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cancer cells (42-45). Polyphenols are also known to have antimicrobial activity. Streptococcus
mutans is one of the examples where antimicrobial action has been demonstrated. S. mutans is a
primary microbial agent in the pathogenesis of dental caries. It was shown that polyphenols can
inhibit biofilm formation and acid production by S. mutans. One of the pathways through which
polyphenols are active against S. mutans is by the inhibition of proton-translocating F1-ATPase
activity (46,47).

One important aspect of polyphenols is their ability to selective and unselective binding
with biologically important molecules such as proteins. This is made possible by the presence of
multiple polar functional groups that interact with proteins strongly and inhibit them (41,48).

Earlier, polyphenols resveratrol, piceatannol, and quercetin were shown to prevent
synthetic and hydrolytic activities of bovine mitochondrial ATP synthase by blocking clockwise
or anti-clockwise rotation of the γ-subunit. Fig. 2 shows the recently solved F1-reseveratrol, F1piceatannol, and F1-quercetin complex structures from bovine ATP synthase by molecular
replacement using data to 2.3, 2.4, and 2.7 Å, respectively. The distinct binding pocket for
resveratrol, piceatannol, and quercetin lies between the βTP-subunit and the C-terminal region of
γ-subunit (49). Polyphenols resveratrol, piceatannol, and quercetin were also shown to bind in a
slightly distorted planar conformation through H-bonds and hydrophobic interactions. The
hydrophobic interactions occur between the inhibitors and γLys-260, γIle-263, βTPVal-279, and
βTPAla-278. Polyphenol inhibited mitochondrial ATP synthase (E. coli residue numbers used
throughout). X-ray structures also show that residues γAla-256, γThr-259, γGlu-264, αTPGlu292, αTPGly-290, and αDPGlu-292 are within 4Å of the bound compounds thus providing
additional non-polar interaction (49).
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Figure 2. X-ray Structures of Mitochondrial ATP Synthase Showing Resveratrol, Piceatannol, or
Quercetin. Rasmol software was used to generate these figures. PDB files used were 2jj1, 2jj2,
and 2jjZ (50). (A) Reacted resveratrol in contact with α-, β-, and γ-subunits. (B) Reacted
piceatannol in contact with α-, β-, and γ-subunits. (C) Reacted quercetin in contact with α-, β-,
and γ-subunits. Green color represents α-subunit, cyan color is for β-subunit and blue color is for
γ-subunits. Residues involved in the interaction with compounds are identified. γQ274K, γT277I
in red is showing the difference between bovine and E. coli ATP synthase. In place of Q and T
bovine has K and I residues. E. coli residue numbering is shown. At the bottom E. coli and
bovine α-, β-, and γ-subunit binding pocket residue are aligned.
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We studied the inhibitory effects of natural polyphenols resveratrol, piceatannol,
quercetin, quercetrin, or quercetin-3-β-D glucoside (see Fig. 3), and their derivatives on E. coli
ATP synthase. Resveratrol is an antimicrobial substance naturally produced by plants when they
are under attack by pathogens. Piceatannol is a metabolite of resveratrol. Quercetin is a plant
derived flavonoid known to shown anti-inflamatory and antioxidant properties. Quercitrin and
quercetin-3-β-D glucoside are both derivatives of quercetin (see Table 1). In the present study
our goal was to test (i) if polyphenols resveratrol, piceatannol, quercetin, quercetrin, or
quercetin-3-β-D glucoside inhibit E.coli ATP synthase similar to bovine ATP synthase (ii) if the
beneficial dietary effects of polyphenols are related to their inhibitory actions on ATP synthase,
(iii) if inhibitory effects of polyphenolic compound could be augmented through structural
modifications, and (iv) if they can act as antimicrobial agent through their actions on ATP
synthesis

Hypothesis

We hypothesized that E. coli ATP synthase may follow the inhibitory pathway of bovine
ATP synthase as the basic structure of both are the same.
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Figure 3. Structures of Polyphenol Resveratrol, Piceatannol, Quercetin, Quercitrin, and
Quercetin-3-β-D Glucoside. These structures were drawn using Chem Sketch free version.
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Table 1. Polyphenols Their Molecular Formulas and Synonyms

Name

Molecular

Synonyms

formula
Resveratrol

C14H12O3

3,4′,5-Trihydroxy-trans-stilbene, 5-[(1E)-2-(4Hydroxyphenyl)ethenyl]-1,3-benzenediol

Piceatannol

C14H12O4

(E)-4-[2-(3,5Dihydroxyphenyl)ethenyl]1,2benzenediol, 3,3′,4,5′-tetrahydroxy-trans-stilbene, 3hydroxyresveratol

Quercetin

C15H10O7 · 2H2O

3,3′,4′,5,7-Pentahydroxyflavone dihydrate, 2-(3,4Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1benzopyran-4-one dihydrate

Quercetrin

C21H20O11 · xH2O

hydrate
Quercetin-3-β-D
glucoside

3,3',4',5,7-Pentahydroxyflavone-, 3-(6-deoxy-Dmannopyranoside)

C21H20O12

3,3′,4′,5,7-Pentahydroxyflavone 3-β-glucoside,
Isoquercitrin
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CHAPTER 2
MATERIALS AND METHODS

Source of Polyphenols

Resveratrol (R5100-50MG), piceatannol (P0453-25MG), quercetin dihydrate (Q0125100G), quercetrin hydrate (Q3001-50MG), and quercetin-3-β-D glucoside (17793) were
purchased from Sigma Chemical Company. Polyphenols were suspended in DMSO to obtain the
desired concentrations.

Chemicals

Adenosine 5̍-triphosphate disodium salt, ampicillin, glucose, succinic acid, uracil, TES,
TRIZMA (Tris[Hydroxyethyl]aino ethane), 4-aminobenzamidine dihydrchloride (PAB), and
SDS (Sodium dodecyl sulfate) were purchased from Sigma–Aldrich Chemical Company.

Buffers and Reagents

50 mM Tris-H2SO4(pH 8), ATPase assay buffer, T&S reagent (Tuskey and Shorr
reagent), 10%SDS, TE(trace elements), 1M MgSO4, AET (Argenine Ent Thiamine), ILV
(isoleucin-valine) STEM, TES 50, and TES5 +PAB were prepared as described in Appendix B.
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Culture Media

LB Medium (Luria-Bertani Medium), Minimal media, Limiting glucose, Succinate
media. Preparation of culture media (liquid and plates) is as described in Appendix D.

All other standard chemicals used in this study were ultra pure analytical grade purchased either
from Sigma–Aldrich Chemical Company or Fisher Scientific Company.

Equipment

Stasar III Colorimeter (Gilford, Oberlin, OH) Evolution-300 UV-Visible
Spectrophotometer (Thermo Scientific, Pittsford, NY), French press, cell disrupter (Thermo
Scientific, Asheville, NC), C76 Water Bath shaker (New Brunswick Scientific Co. inc, Edison,
NJ ). Sorvall WX ultra-80, Ultra Centrifuge (Thermo Scientific, Asheville, NC), Sorvall RC-5Bsuper speed Centrifuge (Thermo Scientific, Asheville, NC), Series 25, incubator shaker (New
Brunswick Scientific Co. inc, Edison, NJ ).
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Experimental Methods

Schematic Representation of Preparation of E. coli Membrane Bound ATP Synthase
E. coli (pBWU 13.4/DK8) culture in MM (37oC, 250 rpm)

Pellet at 9500 rpm x 15 min

Resuspend pellet in STEM
Spin at 9500 rpm x 25 min

Resuspend pellet in 2 ml Stem/g wet cells
Add DNAse
French press 2 K psi

Spin
22 K rpm x 20 min

Spin supernatant
60 K rpm x 2 hrs at 2oC

Resuspend pellet in TES 50
Spin at 60K rpm x 2hrs at 2oC

Resuspend pellet in TES 5 + PBA
Spin at 60K rpm x 2hrs at 2oC
Repeat this step / store at - 70oC
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Membrane bound ATP synthase were purified from E. coli strain pBWU 13.4/DK8 (51,52)

Starter Culture
50 ml of Minimal Media was inoculated with a loop full of E. coli pBWU 13.4/DK8
bacteria and is grown over night at 37°C, 250 rpm (revolutions per minute).

Bacterial Growth
50 ml of overnight starter cultures is inoculated in to 1 lt minimal media and grown at
37oC, 250 rpm. Growth yield was measured at OD595 every hour till late log phase is obtained.
Once the required growth is obtained we proceed to the next step i.e. harvesting cells. For all
subsequent steps the cells are maintained as close to 0oC as possible.

Harvesting Cells
The cells are harvested by spinning the culture at 4oC in a Sorvall RC-5B refrigerated
super speed centrifuge (Fisher Scientific) at 9500 rpm for 15 min. The harvested sample is
resuspended in STEM and centrifuged at 9500 rpm for 25 min. The supernatant is discarded and
the pellet is resuspended in 2 ml STEM/g wet cells and is stored at -80oC overnight.

Cell Fractionation and Membrane Bound ATP Synthase Isolation
Cells from overnight are thawed and mixed with DNAse to digest nucleic acids. The cells
are then disrupted by 2 passages through chilled French press cell fractionator at 2000 psi. Cell
debris was pelleted by centrifugation at 18K rpm for 20 min using Sorvall WX ultra-80, Ultra
Centrifuge. Subsequently, the membranes were pelleted by spinning the supernatent at 60K rpm
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for 120 min. The membrane is then resuspended in TES 50 and centrifuged at 60K rpm for 120
min. The pellet is then washed with TES 5 + PAB by spinning twice at 60K rpm for 90 min.
Finally the purified membrane is resuspended in 50mM Tris Sulfate (pH 8) and stored at -80oC.

Membrane Bound ATP Synthase Concentration and ATPase Assay
Membrane concentrations were found by plotting the absorbance at 595 nm using
Bradford reagent against standard BSA curve. ATPase activity was measured by adding 1 ml
assay buffer containing 10 mM NaATP, 4 mM MgCl2, 50 mM TrisSO4 (pH 8) to the purified F1
or membranes at 37°C and stopped by addition of SDS to 3.3% final concentration. Pi released
was assayed by adding 1 ml of T&S reagent containing 10 mM (NH4)6Mo7O24·4H2O , 250 mM
Fe(NH4)2(SO4)2·6H2O and 1.176 N H2SO4 (53). The color thus developed was measured using
Stasar III Colorimeter at 700 nm. A graph is plotted using Sigma plot software with activity on
X-axis and OD700 on Y-axis. There is a straight line relationship between the calorimetric
reading and the concentration of phosphorus. The reaction is as follows
ATP + ATP synthase ⇌ ADP + Pi
Pi + T & S → blue color measured at OD700

ATP synthase activity was calculated using the formula
(Average Sample OD - Average Blank OD) =_____ µmol/min/g protein
Amount of protein (mg) x Time (min)
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Inhibition of ATPase Activity by Resveratrol, Piceatannol, Quercetin, Quercetrin, or Quercetin3-β-D Glucoside
Membranes or purified F1 at a concentration of 0.2–1.0 mg/ml were preincubated with
varied concentrations of resveratrol, piceatannol, quercetin, quercetrin, or quercetin-3-β-D
glucoside for 60 min at room temperature, in 50 mM TrisSO4 pH 8.0. Then 1 ml ATPase assay
buffer was added to measure the activity. The reaction is stopped by addition of SDS to 3.3%
final concentration. Pi released was assayed by adding 1 ml of T&S reagent containing 10 mM
(NH4)6Mo7O24·4H2O, 250 mM Fe(NH4)2(SO4)2·6H2O, and 1.176 N H2SO4 . The color thus
developed was measured using Stasar III Colorimeter at OD700 nm. A graph is plotted using
Sigma plot software with compound concentration on X-axis and relative ATPase % specific
activity on Y-axis. This gives the enzyme activity with different concentrations of the compound
in a linear decay fashion. It should be noted that prior to the experiments, F1 samples (100 µl)
were passed twice through 1 ml centrifuge columns with Sephadex G-50 beads equilibrated in
50 mM TrisSO4 pH 8.0, to remove catalytic site bound-nucleotide.

% Specific activity was calculated using the formula
__
100
=_____ µM
Specific activity of the blank X Specific activity of the test (min)

25

Confirmation of Extent of Inhibition by Extra Pulse Experiment
To check if the inhibition is complete and there is no degradation of the compound and
extra pulse experiment was performed. Membranes or purified F1 at a concentration of 0.2–
1.0 mg/ml were preincubated with inhibitory concentration of the compound for 60 min at room
temperature, in 50 mM TrisSO4 pH 8.0. Then another pulse of the compound with inhibitory
concentration was added to the tube and incubated for 60 more min at room temperature. 1 ml
ATPase assay buffer was added to measure the activity. The reaction is stopped by addition of
SDS to 3.3% final concentration. Pi released was assayed by adding 1 ml of T&S reagent. The
color thus developed was measured at OD700 nm. Control tubes with single dose of compound
incubated for 120 min were also performed. A graph is plotted using Sigma plot software with
compound concentration on X-axis and relative % specific activity on Y-axis.

Reversal of Purified F1 or Membrane Bound Enzyme ATPase Activity from Resveratrol,
Piceatannol, Quercetin, Quercetrin, or Quercetin-3-β-D Glucoside Inhibition
To check if the inhibition of ATPase activity is reversible or not, reversibility
experiments were performed. Reversibility of inhibition was performed on both membrane
bound enzyme and on purified F1 protein. It is assayed by dilution of the membrane enzyme and
by passing the inhibited purified F1 through centrifuge columns. Membranes were first reacted
with the highest inhibitory concentrations for 1 h at room temperature. These concentrations
were used based on the maximal inhibition of the ATP synthase. Then 50 mM TrisSO4 pH 8.0
buffer was added to decrease the concentrations to a minimal noninhibitory concentrations, and
incubation continued for 1 additional hour at room temperature before ATPase assay.
Reversibility was also tested by passing the polyphenol inhibited purified F1 enzyme twice
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through 1 ml centrifuge columns before measuring the ATPase activity. Control samples without
the compounds were also incubated for the same time periods as the samples as 2 consecutive
passages through centrifuge columns were previously found to decrease the concentration of
small molecules bound to ATP synthase and other proteins to non-detectable levels. Thus, after
passage through centrifuge columns, reactivation is likely a first-order kinetic process that is a
function of release of bound inhibitor. After the incubation time regular ATPase assay was
performed to check the membrane activity.

Effects of Polyphenols on E. coli Growth
Inhibitory effects of polyphenols on E.coli cell growth were studied by growing the E.
coli strain pBWU13.4 on succinate plates, limiting glucose, or LB media in presence of
polyphenols. Growth in the liquid media was performed by inoculating LB or limiting glucose in
a 16 well culture plate with ATP synthase inhibitory concentrations of polyphenols. The cultures
were grown overnight at 37oC at 250 rpm. Growths were measured at OD595 nm and are
compared with the control cultures without any inhibitors. Plates were prepared by mixing the
inhibitory concentrations of polyphenols in the succinate agar and plated into petri dishes.
Bacterial cultures are then streaked and incubated at 37oC and the growth was recorded by
visually inspection of the number of colonies and size of colonies for 3 days along with the
control.
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CHAPTER 3
RESULTS
Inhibitory Effect of Resveratrol, Piceatannol, or Quercetin on the Purified F1 or Membrane
Bound E. coli ATP Synthase Enzyme
We studied the inhibitory effect of resveratrol, piceatannol, quercetin, quercetrin, or
quercetin-3-β-D glucoside (Fig. 3) on the purified F1 and membrane bound ATP synthase of E.
coli. Figure 4 shows the inhibition of ATPase activity of purified F1 or membrane bound enzyme
in presence of varied concentrations of resveratrol, piceatannol, or quercetin. Complete, potent
inhibition (~100% inhibited; IC50 ~14 µM) occurs in presence of piceatannol without any
residual activity, the maximum amount of inhibition in presence of quercetin was slightly less
(~80%; IC50 ~33 µM) with 20 % residual activity, and resveratrol appear to be the least potent
inhibitor (~40% inhibited; IC50 ~94 µM) with 60% residual activity. We consistently found that
the F1 data and the membrane data were the same for these inhibitors. Earlier studies established
that inhibition of ATPase activity can be assayed using either membrane preparations or purified
F1 with same results (54,55).

28

Figure 4. Inhibition of ATPase Activity in Purified F1 or Membrane Bound ATP Synthase by
Resveratrol, Piceatannol, or Quercetin. Membranes or purified F1 were preincubated for 60 min
at 23 °C with varied concentration of resveratrol, piceatannol, or quercetin, and then aliquots
added to 1 ml of assay buffer and ATPase activity determined. Details are given in Section 2.
Symbols used are: circles (● and ○), resveratrol; squares (■ and □), piceatannol; triangles (▲ and
), quercetin. Filled symbols are for membranes while open are for purified F1. Each data point
represents average of at least 4 experiments done in duplicate tubes, using 2 independent
membrane or F1 preparations. Results agreed within ±10%vv
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Inhibitory Effect of Quercetrin or Quercetin-3-β-D Glucoside on the Purified F1 or Membrane
Bound Enzyme
Figure 5 shows the inhibitory effect of quercetrin or quercetin-3-β-D glucoside.
Quercetrin shows 40% inhibition with 60% residual activity (IC50 ~120 µM) and quercetin-3-βD-glucoside till 50% with 50% residual activity (IC50 ~71 µM). Again the F1 data and the
membrane data were alike for both the inhibitors.

Figure 5. Inhibition of ATPase Activity in Purified F1 or Membrane Bound ATP Synthase by
Quercitrin or Quercetin-3-β-D Glucoside. Purified F1 or membranes were preincubated for
60 min at 23 °C with varied concentration of quercetrin or quercetin-3-β-D glucoside and then
aliquots added to 1 ml of assay buffer and ATPase activity determined. Symbols used are: (
and ), quercitrin; ( and ), quercetin-3-β-D glucoside. Filled symbols represent membrane
data while open symbols represent data for purified F1. Each data point represents average of at
least 4 experiments done in duplicate tubes, using 2 independent membrane or F1 preparations.
Results agreed within ±10%.
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Confirmation of Extent of Inhibition by Extra Pulse Experiment
In previous studies (54-60), it has been noted in several instances where ATP synthase
was incompletely inhibited by potent inhibitors like fluoroaluminate, fluoroscandium, sodium
azide, or NBD-Cl. In recent studies also it was found that E. coli ATP synthase is partially
inhibited by several polyphenols like hesperidin, chrysin, kaempferol, diosmin, apigenin,
genistein, or rutin in the range of 40–60% (61). Even several peptides like aurein, carein,
magainin, or magainin II-amide inhibited E. coli ATP synthase partially (62). Our polyphenols
also showed some residual activities so to be sure that the maximal inhibition with resveratrol,
piceatannol, quercetin, quercetrin, or quercetin-3-β-D glucoside had been reached we performed
extra pulse experiment where we incubated each membrane preparation or purified F1 with the
inhibitory concentrations of the compounds i.e. 376 µM resveratrol, 50 µM piceatannol, 100 µM
quercetin, 400 µM quercetrin, or 376 µM quercetin-3-β-D glucoside for 1 h as in Figs. 4 and 5
followed by an extra pulses of the compounds doubling the concentrations of the polyphenols in
the reaction mixture and continued the incubation for an additional hour and assayed ATPase
activity. As shown in Fig. 6A and B very little or no additional inhibition occurred consistent
with Figs. 4 and 5 data. This shows that the inhibition by resveratrol, quercetin, quercetrin, or
quercetin-3-β-D glucoside was maximal and fully inhibited F1 or membranes retained residual
activity and the inhibition achieved is maximal. Although we used 1 h incubation time, it was
observed that the maximal inhibition of purified F1 or membrane bound enzyme was achieved
within 15 min.
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Figure 6. Results of Extra Pulse of Resveratrol, Piceatannol, Quercetin, Quercitrin, or Quercetin3-β-D Glucoside on Purified F1 or Membrane Bound ATP Synthase. (A and B) Membrane bound
ATP synthase (Mbr, gray background) or purified F1 (F1, white background) was inhibited with
376 µM resveratrol, 50 µM piceatannol, or 100 µM quercetin, 400 µM quercetrin, or 376 µM
quercetin-3-β-D glucoside for 60 min under conditions as described in Fig. 4 and Fig. 5. Then a
further pulse of 376, 50, 100, 400, and 376 µM for resveratrol, piceatannol, quercetin, quercetrin,
or quercetin-3-β-D glucoside, respectively, was added and incubation continued for 1 h before
assay.

Reversal of ATPase Activity of Purified F1 or Membrane Enzyme from the Resveratrol,
Piceatannol, Quercetin, Quercetrin, or Quercetin-3-β-D Glucoside Inhibition

Here we examined whether the inhibition of ATP synthase by the polyphenols is
reversible or not. This experiment was carried out in 2 ways (i) the purified F1 or membrane
bound enzyme was inhibited with the higher concentration of resveratrol, piceatannol, quercetin,
quercetrin, or quercetin-3-β-D glucoside. Then the samples were diluted to a noninhibitory
concentration. It was found that the inhibition was totally reversible (Fig. 7A and B). (ii) 20 µg
purified F1 samples were inhibited with 470 µM resveratrol, 50 µM piceatannol, 94 µM
quercetin, 400 µM quercetrin, or 400 µM quercetin-3-β-D glucoside for 1 h. Again these
inhibitory concentrations were determined based on data from Fig. 4 and 5. Then they were
passed twice through 1ml centrifuge columns and ATPase activity was measured. It was found
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that in all cases activity was restored back to the near normal level as seen in Fig. 6C and D as in
absence of the compounds similar to Fig.7A and B. These data indicate that the observed
inhibition is not the result of protein denaturation and that the enzyme retains the ability to
reactivate upon release of the compound after dilution.
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Figure 7. Reversibility of Inhibition. (A and B) Results of reversibility through dilution of
membrane bound ATP synthase (Mbr, gray background) or purified F1 (F1, white background).
Membrane/F1 was incubated with 470 µM resveratrol, 50 µM piceatannol, 94 µM quercetin, 400
µM quercetrin, or 400 µM quercetin-3-β-D glucoside for 60 min under conditions as described in
Figs. 2 and 3. Concentrations were lowered to 10-fold by adding TrisSO4 buffer and incubation
continued for 1 h before assay. The first bars are purified F1 or membrane enzyme with no
compound (F1/Mbr), followed by resveratrol (RT), piceatannol (PA), quercetin (QD), quercitrin
(QH), or quercetin-3-β-D glucoside (Q3G) from left to right. The last digits represent the
compound concentrations. (C and D) Reversibility through centrifuge columns. 20 µg purified F1
samples were inhibited with 470 µM resveratrol, 50 µM piceatannol, 94 µM quercetin, 400 µM
quercetrin, or 400 µM quercetin-3-β-D glucoside for 1 h and were passed twice through 1ml
centrifuge columns and ATPase activity was measured. It was found that in all cases activity was
restored back to the near normal level as in absence of the compounds similar to Fig.7A and B.
The first bars are purified F1 with no compound (F1/Mbr), followed by resveratrol (RT),
piceatannol (PA), quercetin (QD), quercitrin (QH), or quercetin-3-β-D glucoside (Q3G) from left
to right. The last digits represent the compound concentrations and CC represents the reaction
which is passed through the centrifuge column.
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Growth Assays: Inhibition of Growth on LB, Limiting Glucose, and Succinate Medium in
Presence of Resveratrol, Piceatannol, Quercetin, Quercitrin, or Quercetin-3-β-D Glucoside
Inhibitory effects on ATP synthesis were studied by growing the E. coli strain
pBWU13.4 on succinate plates, limiting glucose, or LB media in presence or absence of
resveratrol, piceatannol, quercetin, quercitrin, or quercetin-3-β-D glucoside. We found that
pBWU13.4 growth was inhibited in presence of resveratrol or piceatannol but was not affected in
presence of quercetin, quercitrin, or quercetin- 3-β-D glucoside. Loss of growth on succinate
plates and limiting glucose suggests the loss of oxidative phosphorylation (see Table 2).
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Table 2. Effects of Polyphenols on the E. coli Cell Growth.
Growth on succinate

Growth yield in

Growth on LB mediab

platesa

limiting glucoseb (%)

(%)

Polyphenols

Controlc

++++

100

100

Nullc

−

43

45

Resveratrol

−

42

43

Piceatannol

−

43

44

Quercetin

++++

96

98

Quercitrin

++++

96

97

++++

97

98

Quercetin-3-β-D
glucoside

a

Growth on succinate plates after 3 days was determined by visual inspection.
(++++) High growth; (−) no growth.
b
Growth yield on limiting glucose and LB was measured as OD595 after ~20 h growth at 37 °C.
c
Control, pBWU13.4/DK8; null, pUC118/DK8. Growth of positive and negative controls in
absence of polyphenol compounds. Data are means of 4 to 6 experiments each at 37 °C. Each
individual experimental point is itself the mean of duplicate assays.
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CHAPTER 4
DISCUSSION
A variety of inhibitors are known to bind and inhibit ATP synthase enzyme. Recent
finding showed that polyphenols: resveratrol, piceatannol, and quercetin inhibit bovine heart
mitochondrial ATP synthase by blocking both clockwise and anti- clockwise rotation of the γsubunit. X-ray crystallography at 2.3, 2.4, and 2.7-Å resolution showed that these polyphenol
compounds bind between the C-terminal tip of the γ-subunit and the βTP subunit through
hydrophobic interactions and H-bonds. The hydrophobic interaction between the inhibitor
compounds and mitochondrial enzyme was shown to involve γK260, γI263, βTPV279, and
βTPA278. Other residues, which are within 4 Å of the bound compounds and contribute to nonpolar interactions, are γAla-256, γThr-259, γGlu-264, αTPGlu-292, αTPGly-290, and αDPGlu-292.
Two H-bonds are also formed between βTPV279 and αTPGlu-292 and the bound polyphenol
compounds Figure. 2. (49). The equivalent residues in the E. coli enzyme are γQ274 (γK260),
γT277 (γI263), βTPV265 (βTPV279), and βTP264 (βTPA278) (63). Parentheses show the bovine
numbers. The focus of our study is to examine the inhibitory role of polyphenols resveratrol,
piceatannol, quercetin along with quercitrin, and quercetin-3-β-D glucoside on the E. coli ATP
synthase. The aim of our study is to test (i) if the beneficial effects of polyphenols are related to
their inhibitory actions on ATP synthase, (ii) if inhibitory effects of polyphenolic compound
could be augmented through structural modifications, and (iii) if they can act as antimicrobial
agent through their actions on ATP synthesis.

By using E. coli membrane preparations, we have tested polyphenols resveratrol,
piceatannol, quercetin, quercitrin, or quercetin-3-β-D glucoside on the activity of F0F137

ATPase/ATP synthase. We also screened the effect of these polyphenols on purified F1 protein
that is similar to that of the membranes. We found out that polyphenols resveratrol, piceatannol,
quercetin, quercetrin, or quercetin-3-β-D glucoside inhibited E. coli ATP synthase to varying
degrees ( Fig. 4 and 5). Piceatannol causes maximal inhibition with 0% residual activity with
IC50 values of ~14 µM. Other inhibitors, resveratrol has a residual activity of 25% with IC50
values of ~94 µM, quercetin has a residual activity of 25% with IC50 values of ~33 µM,
quercetrin has a residual activity of 40% with IC50 values of ~20 µM, and quercetin-3-β-D
glucoside has a residual activity of 50% with IC50 values of ~71 µM. These results are not
consistent with earlier findings of bovine ATP synthase whose inhibitory concentrations for
resveratrol, piceatannol, and quercetin were 19 µM, 8 µM, and 65 µM, respectively (49). The
reason for this might be due to the differences in the amino acids at the binding sites of
polyphenols in bovine and E. coli ATP synthase.

Though resveratrol and quercetin like piceatannol are composed of 2 phenolic rings did
not significantly inhibit the ATP synthase even at higher concentrations. The reason for this
might be because of differential numbering / positioning of OH groups on the phenol rings. Like
quercetin its derivatives quercetrin and quercetin-3-β-D glucoside did not inhibit the enzyme to
the extent as quercetin did. It may be due to the presence of the third phenol ring that might have
caused steric hindrance resulting in low inhibition rates. The difference in the rate of inhibition
clearly indicates the importance of hydroxyl groups in particular positions and the number of
phenolic rings.

Additional dose of compounds to the previously inhibited purified F1 or membranes did
not change the degree of inhibition significantly (6A and B). This suggests that the inhibition of
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purified F1 or membrane by the phenolic compounds was the true and maximum achievable. The
process of inhibition was also found to be completely reversible. A completely inhibited F1
regained its activity when it was passed through the centrifuge columns that resulted in removal
of the bound compound with the enzyme. Similarly, purified F1 or membrane regained complete
activity once it was brought back to lower concentrations of compound after exposing it to
higher concentrations by dilution with buffer and by passing it through centrifuge columns (Fig.
7A,B,C and D) This shows that the compound and the enzyme share a non-covalent interaction.

Another important aspect observed is the bacterial growth patterns in presence of the
phenolic compounds. Resveratrol and piceatannol restricted the growth of E. coli suggesting that
both ATP hydrolysis and ATP synthesis are inhibited. This finding is consistent with the effect
of resveratrol and quercetin observed on bovine ATP synthase (49). Quercetin, quercetrin, or
quercetin-3-β-D glucoside prevents only ATP hydrolysis and not the ATP synthesis suggested by
the growth of the bacteria in the presence of the compound. The reason for this performance is
unknown but can be speculated by the following reasons (a) as observed the inhibition of the
enzyme by these compounds is not complete because of which the bacterial are able to survive
(b) the inhibitors could not pass the cell wall to react with the membrane (c) inhibitors got
pumped out by an export pump, (d) the inhibitors were metabolized by the bacterial cells. More
inhibitory studies by new functionally modified polyphenol compounds should help in
understanding this difference.

Our studies show that the inhibition of ATP synthase could be a potential mechanism
contributing to the many effects of dietary polyphenols. Mitochondrial dysfunction is the cause
of a number of degenerative diseases such as cancer, neurological disorders, and cardiovascular
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disease (64,65). Therefore, it is acceptable that the inhibition of the ATP synthase by piceatannol
and other related compounds might play a significant role in the pathophysiology of such
conditions (49). For example, inhibition of mitochondrial F1Fo-ATPase by dietary polyphenols
might be beneficial is by induction of apoptosis selectively in tumor cells. Resveratrol is known
to induces cell death in tumor cells via pathways that depend on mitochondria (44,66), and
another inhibitor, oligomycin, has similar effects on mitochondrial F1Fo-ATPase (49), possibly
by specifically marking tumor cells for cell death by CD14, while assuring differentiation to
occur in the surviving population (49). Alteration of cellular bioenergetics is another vital way of
triggering the cell death. The benzodiazepine Bz-423 inhibits the mitochondrial F1Fo-ATPase by
binding to the oligomycin sensitivity-conferral protein, a component of the peripheral stalk
resulting in apoptosis. Nontumor cells are not affected by the drug, but the autoimmune
lymphocytes with altered mitochondrial bioenergetics, are sensitized to Bz-423-mediated
inhibition of ATP synthase (49).

The resistance of mycobacterium against the anti-tuberculosis drug diarylquinoline is due
to two C-subunit mutations D32V and A63P. This commends a need for more potent natural or
synthetic inhibitors that can specifically target bacterial ATP synthase enzymes (24). The
inhibition of biofilm formation and acid production by S. mutans through the inhibition of
proton-translocating F1-ATPase activity in presence of a variety of polyphenols (46,47) along
with the knowledge of inhibitory effects of polyphenols on E. coli ATP synthase could provide
starting point to develop inhibitors against bacterial pathogens such as Mycobacterium
tuberculosis and S. mutans.
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Thus, by identifying and modeling potent polyphenol inhibitors that can selectively
induce apoptosis through inhibition of the F1Fo-ATPase, we can treat diseases caused by
mitochondrial dysfunction and can even design anti microbial drugs.
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APPENDICES
APPENDIX A: Abbreviations
ATP - Adenosine triphosphate
ADP- Adenosine diphosphate
F1- F1 protein
Gln – Glutamine
IC50- half maximal inhibitory concentration
Ile – Isoleucine
Lys - Lysine
Mbr- Membrane
PA - Piceatannol
Pi- Inorganic phosphate
Q3G - Quercetin-3-β-D glucoside
QH - Quercetrin hydrate
QD - Quercetin dihydrate
RT - Resveratrol
Thr - Threonine
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APPENDIX B: Buffers and Reagents
50 mM Tris-SO4 buffer
To 90 ml H2O add
0.61 g Tris
Adjust pH to 8.0 with H2SO4
Bring to a final volume of 100 ml with H2O
ATPase cocktail
In 150 ml H2O add
10 ml 1 M Tris
0.8 ml 1M MgCl2
5 ml 0.4 Na ATP (Adenosine 5̍-triphosphate disodium salt)
Adjust pH to 8.5 with H2SO4
Bring to a final volume of 200 ml with H2O
Freeze in plastic bottles at -20oC
10 % SDS
100 gm Sodium dodecyl sulfate
Bring to a final volume of 1000 ml with H2O
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T & S reagent / Tuskey and Short reagent
Sol A: 1.2 g Ammonium molybdate ((NH4)6Mo7O24·4H2O in 9.8 ml 12 N H2SO4)
Sol B: 10 g Ferrous ammonium sulfate (Fe(NH4)2(SO4)2·6H2O in 70 ml H2O)
Add sol A to sol B while stirring
Bring to a final volume of 100 ml with H2O
Store at 4oC
STEM
To 700 ml H2O add
100 ml 1 M TES
4.29 g Mg(CH3CO2)2·4H2O
85.5 g sucrose
0.0951 g EGTA (Ethylene glycol-bis(2-aminoethylether)-N,N,N,N-tetraacetic acid)
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)
Adjust pH to 6.5 with NaOH
Bring to a final volume of 1000 ml with H2O
Freeze in plastic bottles at -20oC
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TES 50
To 700 ml H2O add
50 ml 1 M TES
150 ml glycerol
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)
1 g PAB (4-Aminobenzamidine dihydrochloride)
Adjust pH to6.5 with NaOH
Bring to a final volume of 1000 ml with H2O
Freeze in plastic bottles at -20oC
TES 5 + PAB
To 700 ml H2O add
5 ml 1 M TES
150 ml glycerol
1 ml 0.5 M DTT (Dithiothreitol)
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)
1 g PAB (4-Aminobenzamidine dihydrochloride)
2.5 ml 0.2 M EDTA (Ethylenediaminetetraacetic acid disodium salt dihydrate)
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Adjust pH to 6.5 with NaOH
Freeze in plastic bottles at -20oC
AET (Argenine Ent Thimine)
To 60 ml H2O add
0.617 g 2,3 Dihydroxy Benzoic acid
16.86 g L-Arginine HcL
1 ml 20 mM Thiamine
Add just enough amount of NaOH to dissolve everything
Make final volume to 100 ml with H2O
Filter sterile
TE (Trace Elements)
To 80 ml H2O
0.251 g Zinc Sulfate (ZnSO4.7H2O)
0.017 g Manganese Sulfate (MnSO4.H2O)
0.029 g Boric acid (H3BO3)
0.012 g Calcium Sulfate (CaSO4.2H2O)
0.037 g Calcium Chloride (CaCl2.2H2O)
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0.049 g Ferric Chloride (FeCl3.6H2O)
Make final volume to 100 ml with H2O.
Filter sterile
ILV (Isoleucin-Valine)
To 95 ml H2O add
0.394 g Isoleucine
0.352 g Valine
Make final volume to 100 ml with H2O
Filter sterile
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APPENDIX C: Culture Media and Plates
LB liquid medium
12.5 g of LB broth powder
Add H2O to bring to 500 ml
Autoclave for 30 minutes
Cool the media to ~50oC
Add 500 µl of 100 mg/ml Ampicillin
Minimal Glucose
To 400 ml H2O add
5.225 g Potassium Phosphate Dibasic Trihydrate (K2HPO4)
2.40 g Sodium Phosphate Monobasic (NaH2PO4)
0.99 g Ammonium Sulfate ((NH4)2SO4)
Autoclave for 30 min, cool it and add the following additions
10 ml Uracil
10 ml 27 % Glucose
5 ml ILV (isoleucin-valine)
0.5 ml TE (trace elements)
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0.5 ml 1 M Magnesium Sulfate (MgSO4)
0.5 ml AET (Argenine Ent Thimine)
0.5 ml 100 mg/ml Ampicillin
0.312 ml 4X LB
LB-Agar plate with Ampicillin
12.5g of LB broth powder
7.5g of agar
Bring to a final volume of 500 mL
Autoclave for 30 minutes
Cool the media to ~50oC
Add 500 µl of 100 mg/ml Ampicillin
Pour into sterile plates
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